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Abstract: Azithromycin extended release (Zmax®, Pﬁ  zer Inc) is a novel single-dose admin-
istration formulation of azithromycin which won FDA approval in June 2005 and is currently 
approved for the treatment of community acquired pneumonia and acute bacterial sinusitis. 
Azitromycin is incorporated into sustained-release microspheres which release the drug slowly 
through 200 μm pores. Because of this sustained release mechanism, most of the drug is released 
into the lower gastrointestinal tract, reducing gastrointestinal side-effects, and allowing for a 
higher dose to be administered. The unique pharmacological properties and extremely long half-
life of azithromycin make this drug well suited to single-dose administration but gastrointestinal 
side effects have previously hampered single-dose therapy.
Keywords: azithromycin, microspheres, acute bacterial sinusitis, community acquired 
pneumonia
Introduction
Azithromycin extended release (Zmax®, Pﬁ  zer Inc) is a novel single-dose administra-
tion formulation of azithromycin which won FDA approval in June 2005. It is currently 
approved for the treatment of community acquired pneumonia and acute bacterial 
sinusitis (Zmax package insert). The immediate-release formulation azithromycin has 
been available in the United States since 1992 under the trade name Zithromax®, and is 
approved and widely used for community-acquired pneumonia, acute bacterial sinusitis, 
otitis media, acute bacterial exacerbations of chronic obstructive pulmonary disease, 
pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, urethritis and 
cervicitis, and genital ulcer disease in men (Zithromax package insert). Azithromycin 
revolutionized antibiotic care as it shortened treatment time for infections from 7–14 
days to 1–5 days with comparable efﬁ  cacy. New technology has enabled a higher 
dose to be administered as microspheres thus limiting gastrointestinal side-effects and 
allowing a full course of antibiotics to be given in a single dose.
Pharmacology
Azithromycin is an azolide antibiotic which is similar in structure and function to 
macrolides, but has important differences. It exhibits time-dependent killing, but 
because of its unique pharmacological properties and extremely long half-life (~60 
hours) the pharmacodynamic parameter for these agents that correlates with efﬁ  cacy 
is the area under the curve (AUC) to minimum inhibitory concentration (MIC) ratio 
rather than T > MIC (Odenholt-Tornqvist et al 1995). The AUC to MIC ratio that 
yields maximal efﬁ  cacy with drugs from the macrolide and azolide class in animal 
models is approximately 25 (Craig et al 2002). Whereas penicillin tissue and serum 
levels are roughly equivalent, very little azithromycin remains in the serum and the 
majority concentrates inside cells, notably macrophages and neutrophils. These cells International Journal of Nanomedicine 2007:2(1) 10
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then migrate to areas of inﬂ  ammation, providing extremely 
high concentrations at sites of infection. Azithromycin has 
demonstrated a 500 to 1 concentration difference between 
intracellular and extra cellular sites after 1 hour of incubation 
(Gordan and Blumer 2004).
As more pharmacodynamic information was gained on 
azithromycin it became apparent that shorter courses of 
therapy and at least equivalent efﬁ  cacy can be achieved by 
frontloading the drug and delivering more drug early in infec-
tion. Animal studies have shown that the 50% effective dose 
can be decreased by giving a larger dose in 1 day compared 
with the same dose divided over 3 days. This translated into 
more rapid eradication of bacteria in a gerbil model of otitis 
media (Girard et al 2002).
Azithromycin extended release is incorporated into 
sustained-release microspheres. These microspheres are 
approximately 200 μm in diameter and release the drug 
through pores. The pore size is in the nanometer range and 
is ideally suited for the slow release of the active medica-
tion once the microsphere has passed through the stomach. 
Because of this sustained release mechanism, most of the 
drug is released into the lower gastrointestinal tract, reducing 
gastrointestinal side-effects, and allowing for a higher dose to 
be administered (Breen et al 2005). Azithromycin extended 
release delivers 2 g of azithromycin in one dose while the 
immediate release 3- and 5-day courses deliver 1.5 g over 
their entire dosing period.
This 2 g extended-release dose results in higher peak 
serum concentrations and pharmacokinetic parameters of 
azithromycin compared with conventional preparations. 
The peak serum concentrations 24 hour AUC (0–24) on day 1 
are 3-fold higher for azithromycin extended release 2 g vs 
the traditional 1.5 g azithromycin given over either 3 or 5 
days: 0.85 μg/mL vs 0.39 μg/mL and 0.85 μg/h/mL vs 0.39 
μg/h/mL, respectively (Pﬁ  zer Inc, data on ﬁ  le).
Drug levels are also higher at sites of infection, namely 
lung tissue and white blood cells. Sixty-four adults under-
going lung resection were randomly given 2 g azithromycin 
extended release or 500 mg azithromycin. Healthy lung 
tissue was analyzed for AUC (0–24) and was found to have 
3-fold higher levels in those individuals who had received 
azithromycin extended release; 505 μg/h/mL for azithro-
mycin extended release and 130 μg/h/mL for 500 mg. Lung 
tissue drug concentrations after 24 and 72 hours were 25 and 
33 μg/mL, respectively. In another study using azithromycin 
500 mg daily for 3 days concentrations at 24 and 72 hours 
were 9 μg/mL (Pﬁ  zer Inc, data on ﬁ  le; Di Paolo et al 2002). 
In another study 24 healthy adults were randomly given 2 g 
azithromycin extended release or 500 mg azithromycin daily 
for 3 days and white blood cell pharmacokinetics in polymor-
phonuclear leukocytes were analyzed daily for 7 days. The 
front loaded dose resulted in signiﬁ  cantly higher white blood 
cell peak concentrations (Pﬁ  zer Inc, data on ﬁ  le).
Clinical trials
Three industry-sponsored clinical trials have been performed 
comparing 2 g azithromycin extended release with other 
FDA-approved antibiotics for community-acquired pneumo-
nia and acute bacterial sinusitis. Two trials were published 
in 2005 for the treatment of community-acquired pneumonia 
(CAP). D’Ignazio et al (2005) randomized 427 patients to 
receive a single 2 g dose of azithromycin microspheres or 
levoﬂ  oxacin 500 mg daily for 7 days in a double-blinded 
fashion in a multi-center international trial. The primary 
endpoint was clinical response at test of cure which occurred 
14–21 days after initiation of therapy. Patients were all older 
than 18 years of age and had a clinical diagnosis of mild to 
moderate CAP (a Fine mortality risk class of I, II, or III) 
including a chest radiograph with radiographic pneumonia. 
Patients with immune deﬁ  ciency, renal, hepatic, or underly-
ing pulmonary disease that could affect treatment/diagnosis, 
recent antibiotic use or hospitalization, or pregnancy were 
excluded. One hundred and eighty of the 211 azithromycin-
treated patients and 190 of the 212 levoﬂ  oxacin-treated patients 
completed the study. All azithromycin patients were compliant 
with treatment while 10 of the 212 levoﬂ  oxacin-treated patients 
did not complete all seven days of therapy. 50.7% of the 
azithromycin group and 52.8% of the levoﬂ  oxacin group had 
identiﬁ  able organisms. Chlamydophila pneumoniae was most 
common, followed by Staphylococcus aureus, Haemophilus 
parainﬂ  uenzae, Mycoplasma pneumoniae, Staphylococcus 
pneumoniae, and Haemophilus inﬂ  uenzae. None of the S. 
pneumoniae was resistant to levoﬂ  oxacin while seven were 
resistant to azithromycin (MIC > 0.5). Five of these seven 
patients received azithromycin.
At the test of cure the clinical cure rate was statistically 
equivalent with a cure rate of 89.7% for azithromycin and 
93.7% for levoﬂ  oxacin (95% CI, –9.1% to 1.7%). The bac-
teriological cure rate was also equivalent with a cure rate of 
90.7% for azithromycin and 92.3% for levoﬂ  oxacin. Two of 
the subjects with azithromycin-resistant pneumococcus were 
clinical failures but one of these had clearance of organisms 
in the sputum. 12.3% of the azithromycin-treated group 
experienced diarrhea vs 4.7% of the levoﬂ  oxacin-treated International Journal of Nanomedicine 2007:2(1) 11
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group. This largely occurred on days one and two of treat-
ment. There were no serious treatment-related adverse effects 
in either group (D’Ignazio et al 2005).
The second study with CAP, by Drehobl et al (2005), 
compared a single dose of azithromycin microspheres with 
clarithromycin extended release 1 g daily for 7 days. The study 
design was identical to the previous study and randomized 501 
patients, of which 499 were treated and 411 met all inclusion 
criteria. The primary endpoint, again the clinical response at test 
of cure which occurred 14–21 days after initiation of therapy, 
was equivalent for the two arms; 92.6% for the azithromycin-
treated group and 94.7% for the clarithromycin-treated group 
(95% CI, –6.9 to 2.6). There were six S. pneumoniae isolates re-
sistant to azithromycin and clarithromycin. Two were collected 
from the azithromycin-treated group and one of these was a 
clinical failure. This patient also had two other co-pathogens. 
Four were collected from the clarithromycin-treated group 
and two of these were clinical failures. All patients completed 
the azithromycin antibiotic course while 15 of 254 subjects 
did not complete the 7-day clarithromycin course. 12.1% of 
azithromycin-treated patients had diarrhea or loose stools 
compared with 7.5% of clarithromycin-treated patients. These 
episodes were all mild or moderate (Drehobl et al 2005).
The acute bacterial sinusitis study was performed by Murray 
et al (2005) and again was an international, multi-center, double-
blinded, placebo-controlled trial. Five hundred and forty-one 
patients with clinical signs and symptoms and radiographic 
evidence of acute bacterial sinusitis were randomized and 507 
met all inclusion criteria. Patients were excluded if they had 
received any systemic antibiotic therapy in the previous week, 
had recurrent, complicated, or nosocomial rhinosinusitis, or had 
undergone recent (within 3 months) nasal or sinus surgery.
All patients had maxillary sinus aspiration with recovery 
of organisms in 42% of patients. The primary outcome was 
clinical cure (resolution of signs and symptoms or improve-
ment with no need for further antibiotics) at 17–24 days after 
the ﬁ  rst antibiotic dose. Azithromycin and levoﬂ  oxacin were 
equally effective in providing a clinical cure: 94.5% vs 92.8, 
respectively (95% CI, –2.5% to 5.9%). S. pneumoniae was the 
most common pathogen identiﬁ  ed followed by H. inﬂ  uenzae 
and Moraxella catarrhalis. Of 81 S. pneumoniae isolated 57% 
were penicillin susceptible, 27% intermediate, and 16% 
resistant. 85% were azithromycin susceptible while 15% 
were azithromycin resistant (MIC > 2). All strains were 
susceptible to levoﬂ  oxacin. One patient in the azithromycin 
group had a clinical failure with a S. pneumoniae-resistant 
organism, but the repeat sinus aspiration was clear of 
S. pneumoniae and grew Escherichia coli in its place. The 
incidence of diarrhea was 11.1% in the azithromycin group 
and 1.9% in the levoﬂ  oxacin group (Murray et al 2005).
Some authors express concern that this FDA-required 
study design for acute bacterial sinusitis is not a good mea-
sure of antibiotic efﬁ  cacy for acute bacterial sinusitis. Acute 
bacterial sinusitis is largely a self-limited disease with clinical 
resolution seen even in the majority of untreated patients, and 
no study to date has proved clinical superiority over another 
agent. With this established test of cure, patients were evalu-
ated for clinical cure 24–52 days after their symptoms began. 
By this point up to 72% of patients on placebo therapy will 
have resolution of symptoms. The true value of antibiotics 
in acute bacterial sinusitis is more likely faster resolution of 
symptoms enabling patients to return to work or school more 
quickly. In an editorial following Murray et al’s article, Marple 
suggested a more clinically useful primary outcome would 
be difference in time to improvement of symptoms with a 
secondary outcome being quality of life at various intervals 
after initiation of therapy (Marple 2005).
Pneumococcal macrolide resistance
There is a growing number of S. pneumoniae isolates that 
are resistant to macrolides and azolides, but this is not usu-
ally manifested as clinical failures. These drugs exhibit their 
action by inhibiting ribosome function and hence protein 
synthesis. Macrolides interact with bacterial 23S rRNA in 
the 50S subunit. Most resistance has been described via one 
of two mechanisms: a ribosomal methylase coded for by the 
erm gene, and a macrolide-speciﬁ  c cell membrane-based efﬂ  ux 
mechanism, coded for by the mef gene. The altered ribosomal 
binding conferred by the erm mutation confers high level resis-
tance while the efﬂ  ux pump seen with the mef mutation is more 
easily overcome with higher intracellular concentrations of the 
drug. Current NCCLS standards deﬁ  ne macrolide resistance 
as >1 mg/L for macrolides and >2 mg/L for azithromycin. 
Because of the high intracellular concentrations in both respi-
ratory tissue and white cells, these levels are easily overcome 
with azithromycin; however, and few clinical failures are seen 
with azithromycin even with resistant pneumococcus. Some 
authors feel an MIC of >32 mg/L is more indicative of true 
azithromycin resistance (Amsden 1999).
Drug–drug interactions 
and adverse effects
Azithromycin has few drug interactions and does not inter-
act with CYP3A unlike other macrolides. A single dose of International Journal of Nanomedicine 2007:2(1) 12
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azithromycin does not increase prothrombin times in patients 
on warfarin therapy. The major side-effects are gastrointes-
tinal. The overall incidence of gastrointestinal complaints 
is 17.2%, with the above studies all having an incidence of 
diarrhea of 11%–12%. With the immediate-release azithro-
mycin preparation there have been rare reports of hearing 
loss, photosensitivity, angioedema, and cholestatic jaundice 
(The Medical Letter 2005).
Administration
Extended-release azithromycin is a 2 g formulation with a 
cherry-banana taste that is mixed with 60 mL of water by 
the pharmacist. It should be used within 12 hours of mixing 
and taken 1 hour before or 2 hours after a meal. Taking it 
on an empty stomach helps minimize gastrointestinal side-
effects. If the patient vomits within 1 hour of consumption 
an alternative antibiotic should be considered.
Conclusion
Extended-release azithromycin is the only FDA-approved 
single-dose antibiotic for the treatment of community 
acquired pneumonia and acute bacterial sinusitis. This is 
an example of the potential of nanotechnology to improve 
on existing therapies. The active agent, azithromycin, was 
not changed, but the new delivery system has maximized 
pharmacodynamic parameters while allowing for more 
convenient dosing of the drug. Due to the novel microsphere 
formulation gastrointestinal symptoms are reduced compared 
with the 2 g sachet immediate-release azithromycin, but there 
is still a 12% incidence of diarrhea. This drug is especially 
attractive where compliance is an issue because it is ideally 
suited to observed therapy. It also ensures completion of the 
antibiotic course. This, coupled with high ﬁ  rst-day intracel-
lular concentrations when bacterial load is greatest, have the 
theoretical chance of reducing bacterial resistance. How-
ever, these advantages must be weighed against the increase in 
gastrointestinal side-effects and added cost of extended-release 
azithromycin because the immediate-release formulation is 
now generic. Despite improved pharmacodynamic param-
eters, there is no evidence supporting its clinical efﬁ  cacy over 
immediate-release azithromycin. In future we look forward 
to the evolving role of nanotechnology in the pharmaceutical 
ﬁ  eld as it both improves on previous therapy, such as with 
extended-release azithromycin, and also contributes to the 
development of novel treatments.
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